Recursion Pharmaceuticals Inc (RXRX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Recursion Pharmaceuticals Inc (RXRX) has a cash flow conversion efficiency ratio of -0.116x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-105.95 Million) by net assets ($915.00 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market cap of Recursion Pharmaceuticals Inc for the company's overall valuation and market capitalisation.
Recursion Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Recursion Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Recursion Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Recursion Pharmaceuticals Inc ranked by their cash flow conversion efficiency. See how well can Recursion Pharmaceuticals Inc service its debt to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
China Nonferrous Metal Industry’s Foreign Engineering and Construction Co Ltd
SHE:000758
|
-0.124x |
|
Kardigan, Inc. Common Stock
NASDAQ:KARD
|
-0.082x |
|
Integral Ad Science Holding LLC
NASDAQ:IAS
|
0.044x |
|
Taihai Manoir Nuclear Equipment Co Ltd
SHE:002366
|
-0.016x |
|
Shanghai Jahwa United Co Ltd
SHG:600315
|
0.020x |
|
SRH Total Return Fund Inc.
NYSE:STEW
|
0.015x |
|
Dunelm Group plc
F:DFQ
|
0.329x |
|
Douglas Emmett Inc
NYSE:DEI
|
0.034x |
Annual Cash Flow Conversion Efficiency for Recursion Pharmaceuticals Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Recursion Pharmaceuticals Inc from 2019 to 2025. View Recursion Pharmaceuticals Inc (RXRX) share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $1.13 Billion | $-371.81 Million | -0.329x | +5.28% |
| 2024-12-31 | $1.03 Billion | $-359.17 Million | -0.347x | +44.10% |
| 2023-12-31 | $463.44 Million | $-287.78 Million | -0.621x | -261.18% |
| 2022-12-31 | $485.81 Million | $-83.52 Million | -0.172x | +41.15% |
| 2021-12-31 | $542.94 Million | $-158.61 Million | -0.292x | -232.75% |
| 2020-12-31 | $-206.29 Million | $-45.40 Million | 0.220x | -52.06% |
| 2019-12-31 | $-124.27 Million | $-57.04 Million | 0.459x | -- |
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenom… Read more